Transgene – L'immunothérapie contre les cancers

R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

TRANSGENE R&D DAY

Transgene Confirms the Potential of the Intravenous Route
of its Invir.IO™ Oncolytic Viruses against Solid Tumors
with TG6002 Phase I Data Presented at ESMO Congress 2022

2Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

V. Moreno et al. ESMO 2022 Download the poster here Poster Presentation

Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

P. Cassier et al. ESMO 2021 Download the poster here Poster Presentation

Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002

3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses

Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation

Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas

K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation

Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses

20210409 – TG6002 AACR EN

Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

Jérémy Béguin, et al. Sci Rep., January 26 2021 – Read the article Publication

High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma

Tiphaine Delaunay, et al. Molecular Therapy Oncolytics, September 2020 – Read the article and view videos Publication

Cookie	Duration	Description
__cfduid	1 month	The cookie is used by cdn services like CloudFare to identify individual clients behind a shared IP address and apply security settings on a per-client basis. It does not correspond to any user ID in the web application and does not store any personally identifiable information.
viewed_cookie_policy	1 year	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	1 year	This cookie is used to distinguish users on your website. It calculates visitor, session, and campaign data and keeps track of site usage for the site’s analytics report.
_gat_gtag_UA_158044571_1	1 minute	Used to persist session state. More information: https://developers.google.com/analytics/devguides/collection/gtagjs/cookie-usage
_gid	1 day	This cookie is used to distinguish users on your website. It is used to store information on how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected includes the number of visitors, their source, and the pages visited.
vuid	1 year	This domain of this cookie is owned by Vimeo. This cookie is used by vimeo to collect tracking information. It sets a unique ID to embed videos to the website.

menu secondaire

Category: TG6002